Growing public concern about US technology company Palantir’s role in the British health service has prompted warnings from government officials about potential impacts on medical research. The health innovation minister indicated worry that skepticism surrounding Palantir could discourage patients from allowing their health information to be shared with the NHS, which relies on such data for research and planning purposes.
Recent figures show that 60,000 additional people withdrew their medical data through the national data opt-out mechanism during the two-month period from mid-May to mid-July. This increase in opt-outs coincided with heightened media scrutiny of Palantir’s contract with the health service. The government is currently evaluating whether to terminate Palantir’s £330m agreement to operate the NHS’s federated data platform, a system designed to enhance operational efficiency and healthcare outcomes.
Criticism of Palantir centers on its international business relationships and past controversies. Medical professionals and patient advocacy organizations have called for the government to invoke a break clause in the company’s seven-year contract, citing its work with the Israeli military and the US Immigration and Customs Enforcement agency. Additionally, a previous incident involving unauthorized staff access to identifiable patient information has fueled concerns about data security and ethical governance.
Palantir contends that its artificial intelligence technology has delivered measurable improvements to NHS operations, with the company citing statistics including 110,000 additional operations performed and a 15% reduction in discharge delays. However, NHS England stated it cannot establish cause-and-effect relationships from these figures, and the government’s statistics watchdog has initiated an investigation. Similar concerns have extended beyond the health service, with London’s mayor blocking a proposed £50m police contract for Palantir, prompting legal action from the company.
Frith characterized the rise in data opt-outs as modest but acknowledged it would continue to be monitored. He also indicated a potential shift in policy regarding mandatory adoption of the Palantir-controlled platform by NHS trusts, suggesting organizations may now choose alternative solutions to meet local requirements, though the Department of Health clarified that no formal policy change has occurred.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI